Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Inclusion Criteria

• •Confirmed diagnosis of Crohn's disease (CD) for at least 3 months prior to Baseline.
• •Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.
• •Confirmed diagnosis of moderate to severe Crohn's Disease as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic score for CD (SES-CD).
• •Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies.